anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Molecular genetic analysis of tumor tissues is the most important step towards understanding the mechanisms of cancer development; it is also necessary for the choice of targeted therapy. The Hi-C (high-throughput chromatin conformation capture) technology can be used to detect various types of genomic variants, including balanced chromosomal rearrangements, such as inversions and translocations. We propose a modification of the Hi-C method for the analysis of chromatin contacts in formalin-fixed paraffin-embedded (FFPE) sections of tumor tissues. The developed protocol allows to generate high-quality Hi-C data and detect all types of chromosomal rearrangements. We have analyzed various databases to compile a comprehensive list of translocations that hold clinical importance for the targeted therapy selection. The practical value of molecular genetic testing is its ability to influence the treatment strategies and to provide prognostic insights. Detecting specific chromosomal rearrangements can guide the choice of the targeted therapies, which is a critical aspect of personalized medicine in oncology.
An early detection method for preventive medicine for eye disease. A server of an ophthalmic examination support system includes a medical information storage apparatus and a management apparatus. A plurality of clients each capable of communicating with the management apparatus. An association information storage unit for storing association information between predetermined medical information items and ophthalmic examination conditions. An examination condition obtaining unit for obtaining an examination condition associated with the medical information corresponding to patient information. A controller of the client to execute control based on the obtained examination condition. A controller of the management apparatus to receive medical information including examination data of a patient's eye transmitted together with patient information, and to store the medical information in the medical information storage apparatus. A first updating unit of the management apparatus to execute statistical processing of the stored medical information to update the association information.
Disitamab Vedotin 2.0mg/kg q2w+Tislelizumab 400mg q6w. The treatment of Disitamab Vedotin + Tislelizumab will continue until the tumor progression confirmed by imaging, or up to 2 years, or intolerable toxic reactions, or other conditions determined by the researchers.
The present invention concerns methods and compositions involving inhibitors and enhancers of RAD51, a protein involved in homologous recombination. In some embodiments, the present invention concerns methods for stimulating homologous recombination, which has a number of significant research and clinical applications. In certain other embodiments, there are methods for protecting cells using a compound that enhances RAD51 activity. Such enhancers may also be employed to prevent or reduce damage to cells that may be caused by DNA damaging agents. In other embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 enhancer or inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.
PURPOSE:An antitumor agent, containing S-adenosyl-L-methionine or a salt thereof as an active constituent, and administrable for a long term with low toxicity and side effect. CONSTITUTION:An antitumor agent containing S-adenosyl-L-methionine (hereinafter abrreviated to SAM) which is a substance capable of donating methyl groups in the metabolic mechanism of lipid or protein, etc. in the living body or an acid addition salt thereof as an active constituent. The antitumor agent is adminstrable by either one of the oral or the parenteral method, and the daily dose thereof is 1-1,000mg/kg for the oral method and 0.1-50mg/kg for the parenteral method. SAM is obtained by cultivating a microorganism belonging to the genus Saccharomyces, Candida or Mucor, etc. in a cluture medium containing methionine, producing and accumulating SAM, and extracting and purifying the resultant SAM. SAM has the pharmacological action on hepatorrhagia, lipemia and arteriosclerosis, etc.
There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
The VAMC Internal Facilitator will partner with the trial External Facilitators (research team and designated External Facilitators in VISNS 16 and 21) to adapt and implement the study intervention to best meet the needs and preferences of their VAMC site. In addition, each CBOC and clinic affiliated with a VAMC in the Intervention arm will need to identify a Site Champion to provide clinic-specific information to facilitate implementation of the Vaccine Acceptance Intervention at their clinic or CBOC. In addition, for clinics and CBOCs assigned to the Vaccine Acceptance Intervention, VAMC, clinic and CBOC leadership will need to agree to release PACT staff for an initial two-hour Motivational Interviewing (MI) training, and at least one 60-minute post-training consultation session over the one-year trial period. There will be additional consultation sessions offered to intervention clinics and CBOC staff, but these will be optional.
Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
FIELD: fur farming. SUBSTANCE: as a preparation suggested one should use compositions based upon mercury dichloride which are sulfohydrylic groups of proteins at 3% sugar content in reversibly blocked state. Application of suggested compositions increases reproductive function in fur-bearing animals. Moreover, the number of whelped females is increased along with higher mass of the nest and higher mass of animal hide. EFFECT: improved quality of animal fur. 3 ex, 3 tbl
As the initial outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes, coronavirus disease 2019 (COVID-19) has spread beyond Wuhan, China it has become a pandemic affecting over 178 countries. Of patients admitted to the ICU, upwards of 85% developed the acute respiratory distress syndrome (ARDS) and most if not all required mechanical ventilation. The beneficial effects of prone positioning for ARDS have been well described. Coupling the reported benefits of prone positioning in COVID-19 associated ARDS patients with the known beneficial effects of early prone-positioning in the treatment of ARDS, it is not surprising that many hospital systems are advocating prone positioning for treatment of ARDS in patients with COVID-19. However, as the pandemic continues to progress in the United States and the number of new cases grows as new clusters emerge, the possibility of 'rationing' ventilators becomes more real. Therefore, therapies that prevent the need for mechanical ventilation are desperately needed. Given the distinct benefit that patients with COVID-19 have with prone positioning, the overarching hypothesis of this trial is that patients with high risk for respiratory failure may also benefit from prone positioning.
A method utilizing nude mice to provide the reference for the scientific drug administration of tumour patients is characterized in that: tests show that: the cut tumour tissues of the patient are treated and then are planted at the bellies of the nude mice which are generally anesthetized in a subcutaneous way, and the incisions are sealed with tissue adhesives. When the tumours are grown with the average diameter of 6mm and the volume of 100mm<3>, the nude mice with the tumours are randomly divided into a non treatment group (no drug administration group) and groups with different doses to test. The moment is set to be the zero day, and is the time for starting the drug administration. Different drug administration methods of the antitumour drug are determined. The drug administration frequencies and doses are carried out according to the convertion of the normal patient and the requirements of different medicines. The subcutaneous tumour length, width and depth are regularly measured twice a weak to calculate the tumour volume of the time. Meanwhile, the nude mice weight, the dead time and number of the nude mice during the experimental stage are measured. The record data are analyzed, and accordingly, which medicine and what dose have obvious therapeutic effects on the corresponding tumours can be judged.
Contents of the reaction vial are intended only for use in the preparation of Technetium Tc 99m Mebrofenin and are not to be administered directly to the patient.

Delayed or non-visualization of the gallbladder may occur in the immediate post-prandial period or after prolonged fasting or parenteral feeding. Functional biliary obstruction may accompany chronic cholecystitis or pancreatitis. In addition, patients with hepatocellular disease may show non-visualization or delayed visualization of the gallbladder. Delayed intestinal transit may also be noted in such patients. Juvenile hepatitis may be associated with gallbladder non-visualization and the failure to visualize activity in the intestine. Administration of meperidine or morphine may delay intestinal transit of the imaging agent and may result in nonvisualization. Septic patients may show absent or delayed hepatobiliary clearance. Thus, a positive finding does not of itself permit a differential diagnosis of any of the above conditions and should be evaluated in the light of the total clinical picture and results of other diagnostic modalities.

The components of the kit are supplied sterile and nonpyrogenic. Aseptic procedures normally employed in making additions and withdrawals from sterile, nonpyrogenic containers should be used during the addition of the pertechnetate solution and the withdrawal of doses for patient administration.

The Technetium Tc 99m labeling reactions involved in preparing the agent depend on maintaining the stannous ion in the reduced state. Any oxidant present in the sodium pertechnetate Tc 99m supply may, thus, adversely affect the quality of the radiopharmaceutical. Hence, sodium pertechnetate Tc 99m containing oxidants should not be employed.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.

As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient consistent with proper patient management and to ensure minimum radiation exposure to occupational workers.

Tc 99m Mebrofenin should be formulated no more than 18 hours prior to clinical use.
The invention relates to the technical field of analysis methods of single-cell transcriptome data, in particular to a single-cell transcriptome disease specific cell analysis method based on iterative EM clustering. Mainly comprises the following steps: first, cell grouping is performed with a cell marker gene by using a clustering method of a map. Then up-regulating genes and down-regulating genes of a certain cell population of interest in the disease environment are obtained. The cells are then scored and reduced in size to a score space using a scoring algorithm. The analyzed cells were then divided into two groups using an iterative EM clustering algorithm, and the results were then classified into disease-specific cells and normal cells of the control group. The invention provides a set of research methods suitable for single-cell transcriptome data sets under all disease conditions, and provides a new modularized thinking for analysis of the type of data sets.
The present invention relates to methods and pharmaceutical compositions for treating cancer in a subject in need thereof. The inventors investigated for the first time BTN3A2 protein expression using a specific BTN3A2 monoclonal antibody. Thus, the inventors postulated that BTN3A2 overexpression might sensitize AML blasts to Vy9V02 T-cells-mediated lysis. The inventors investigated the role of BTN3A2 in the recognition mechanism of AML blasts by Vy9V52 T-cells. First, the inventors confirmed using co-immunoprecipitation, FRET and PLA experiments that BTN3A2 interacted with BTN3A1 and to a lesser extent with BTN3A3. Next, the inventors generated BTN3A2 knock-out HL-60 cells, as well as a BTN3A1/A3 double KO using CRISPR/Cas9-gene editing. Vy9V52 T-cells were challenged against WT and KO HL- 60 cells, in presence of natural BTN3 ligand (Aminobisphosphonates) or using BTN3 specific agonist mAh. Surprisingly in leukemias lacking BTN3A1 expression, BTN3A2 was still, although to a lesser extent, able to induce AML killing using agonist BTN3A mAh. Thus, the present invention relates to a compound selected from the group consisting of BTN3A2 agonist or BTN3A2 expression activator for use in the treatment of cancer in a subject in need thereof.
Participants receive i.v. infusions with 500 mg Rituximab at 0 and 4 months, followed by placebo infusions (NaCl) at 8 and at 12 months, Pre-treatment prior to all four infusions consists of injection Solu-Medrol 125 mg i.v., tablet Paracetamol 1000 mg p.o. and tablet Cetirizin 10 mg p.o.
Risk Summary

Based on data from animal reproduction studies, Letairis may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy. There are limited data on Letairis use in pregnant women. In animal reproduction studies, Letairis was teratogenic in rats and rabbits at doses which resulted in exposures of 3.5 and 1.7 times, respectively, the human dose of 10 mg per day  [see  Animal Data] . If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential hazard to a fetus [see Contraindications (4.1), Warnings and Precautions (5.1)] . 

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.

Data

Animal Data

Letairis was teratogenic at oral dosages of ≥15 mg/kg/day (AUC 51.7 h∙µg/mL) in rats and ≥7 mg/kg/day (24.7 h∙µg/mL) in rabbits; it was not studied at lower dosages. These dosages are of 3.5 and 1.7 times, respectively, the human dose of 10 mg per day (14.8 h∙µg/mL) based on AUC. In both species, there were abnormalities of the lower jaw and hard and soft palate, malformation of the heart and great vessels, and failure of formation of the thymus and thyroid.

A preclinical study in rats has shown decreased survival of newborn pups (mid and high dosages) and effects on testicle size and fertility of pups (high dosage) following maternal treatment with ambrisentan from late gestation through weaning. The mid and high dosages were 51 ×, and 170 × (on a mg/m 2 body surface area basis) the maximum oral human dose of 10 mg and an average adult body weight of 70 kg. These effects were absent at a maternal dosage 17 × the human dose based on mg/m 2.
The invention discloses a strain 44XB for producing urate oxidase and application thereof, and relates to the technical fields of microorganisms and medicines. The invention provides a strain 44XB for producing urate oxidase, which is deposited in Korean type bacterial deposit center KCTC, deposit No. KCTC 43631, deposit No. 2023, 09, 26, deposit No. 181lpsin-gil. Jeonegeup-si, jeonbuk 56212,South Korea, classified and named Ornithini bacillus sp. The invention also provides application of the strain 44XB in preparing medicines for treating hyperuricemia and gout. The strain 44XB provided by the invention can generate high-activity urate oxidase, can be used for microecological therapy of hyperuricemia, reduces serum uric acid of hyperuricemia, and has potential for being applied to microecological therapy of hyperuricemia and gout.
After arrival to the operating theater, a thoracic US examination will be done using LUS dynamic re-aeration score. Patients will be randomly allocated via sealed opaque envelopes into 2 groups of 30 patients each; control (C) group and minimal dose (Min) group.

For general anesthesia; intubating dose of muscle relaxant will be injected according to the study group; in C group; atracurium 0.5 mg/kg while in min group 0.2 mg/kg will be injected. The trial for intubation will be assessed and recorded. Train-of-four (TOF) stimulation will be maintained less than 2 throughout the intraoperative period in the control group. While, in the min group, boluses of muscle relaxant will be given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal.
PURPOSE: To determine whether periprosthetic drain insertion for hernioplasty using sublay mesh augmentation influences retromuscular fluid collections (RFC) and the clinical course.
METHODS: Forty-two patients with open repair of midline hernias (M2-4, W1, European Hernia Society classification) were allocated to groups with or without retromuscular drains. Subcutaneous drainages were used in both groups to avoid confounding from surgical site occurrences due to superficial, subcutaneous fluid collections. The participants underwent clinical and ultrasound assessments on postoperative days (POD) 14 and 30 to detect RFC, subcutaneous seromas, and wound complications. The sample size was estimated using the RFC of a test cohort with drainage; the assumed relevant volume (5 ml) was calculated comprising 84% (mean + 1 SD) of these patients.
RESULTS: In the retromuscular drainage group, the RFC median volume was reduced by 75.2% on POD 14, and by POD 30, no RFC were found [0.2 vs. 25.8 (p < 0.001) and 0 vs. 4.0 (p = 0.02) on PODs 14 and 30, respectively]. The number of patients with RFC ≥ 5 mL was also significantly lower in the drainage group [4 vs. 12 (p = 0.02) and 1 vs. 8 (p = 0.02) on PODs 14 and 30, respectively]. No surgical site infections occurred in either group, but retromuscular hematoseroma led to one revision surgery and one needle aspiration in the group without drainage. In the drainage group, a significantly longer hospital stay (6.5 days vs. 4 days; p = 0.01) and longer regular analgetic intake (6 vs. 3 days; p = 0.03) were observed. Multivariable regression revealed that retromuscular drainage usage was the only independent predictor of the RFC volume.
CONCLUSION: We found that the use of retromuscular drains after hernioplasty with sublay hernia repair reduced periprosthetic fluid collections in our population but prolonged hospital stay. Whether the reduction of RFC can prevent SSO or revision surgery cannot be determined from our data, the relevance is therefore not assessable. Hence, further larger studies are required to determine the clinical relevance of drains.
FIELD: medicine, pharmacology. SUBSTANCE: heme stimulating agent has the following components, wt. -%: lysine baicaleinate, 15-25; propylene glycol, 35-45; and water, the balance. Agent is used for correction of bone marrow hemopoiesis after effect of ionizing radiation and cytostatics on organism and at hemolytic anemia background. EFFECT: stimulation of bone marrow hemopoiesis suppressed by myeloinhibiting factors. 12 tbl
BACKGROUND: Ruptured vertebral artery dissecting aneurysm (VADA) is often treated surgically with coil embolization and sometimes recurs. We herein report a case of recurrent ruptured VADA after stent-assisted coil embolization (SAC) that was successfully treated with flow alteration surgery using a radial artery (RA) graft.
CASE DESCRIPTION: A 67-year-old woman presented with headache and coma. Enhanced CT revealed subarachnoid hemorrhage due to right VADA. Since the left VA was hypoplastic, the aneurysm was treated with SAC. However, follow-up angiography revealed recurrence of the aneurysm. Additional embolization was not considered due to the small size of the recurrent lesion and the presence of a stent; therefore, flow alteration surgery was performed using a RA graft. There were no neurological deficits after surgery or recurrence.
CONCLUSION: Flow alteration surgery using a RA graft is useful for recurrent VADA after SAC.
Inflammatory bowel diseases (IBD), which include Crohn's disease (CD), ulcerative colitis (UC), undefined IBD and pouchitis (in patients who required IPAA for their colitis) affects about two million people in the world. At this time there is no definitive cure and current treatment is aimed at managing the symptoms and inflammation that accompany these diseases. These diseases are predominantly chronic, and patients may experience various gastrointestinal symptoms depending on the location, nature, and extent of their disease. Both genetic and environmental factors play etiological roles. The overall goal of our research is to understand the etiology and course of these diseases in order to prevent and to manage cases more effectively. In order to do so we are aiming at building a comprehensive database that will include detailed clinical data conjoined with dedicated research information and collection of biological specimens that will target the gut epithelium immune system, the microbiota and specific genetic risk factors.
PROBLEM TO BE SOLVED: To reduce the sterilization rate of a microorganism at the tableting process by allowing fine particles of a specific lipid to contact with or collide to a powder of useful enteric bacterial cells to cover the cells with the lipid and stably and economically obtain a high concentration of bacterial preparation. SOLUTION: In this preparation, useful enteric cell powder is used as a core substance, while fine particles of lipid melting at >=40 deg.C is prepared by melt-mixing an oil and fat melting at >=40 deg.C and an oil and fat melting at <=40 deg.C or subjecting the mixture to ester-interchanging treatment as a lipid membrane material. This lipid membrane material is brought into contact with or allowed to collide to the core substance comprising the useful enteric microorganism powder by stirring to cover or coat the core substance with the lipid membrane material thereby obtaining the objective pressure-resistant, useful enteric bacterial preparation. This preparation is tabulated to give a tablet preparation containing the useful enteric bacterial preparation.  Thus, fluidity increase characterized by lipid-coating preparations, humidity- improving effect and stomach by-passing properties caused by water-breakage are provided. Thus, extremely large improvement effect is integrally shown throughout the tabletting of the useful enteric bacteria, its use and development of its effect.
PURPOSE: A liquid phase composition of an electronic anti-smoking aid is provided to maintain freshness in oral cavity and to ensure a visual effect of expressing smoke. CONSTITUTION: A method for manufacturing a liquid phase composition of an anti-smoking aid comprises: a step of preparing liquid phase concentrate from Berchemia berchmiaefolia (MAK.) KOIDZ. leaves or roots, ginseng or Platycodon grandiflorum (Jacq.) A. DC.; a step of adding spawn to the concentrate and fermenting and maturing the concentrate to prepare a fermented concentrate of pH 3-3.5; a step of adding 40-60 wt% of vegetable glycerin, 1-10 wt% of fermented concentrate, and remaining amount of propylene glycol. The liquid composition additionally contains 0.01-1 wt% of additives of coffee flavor, caffeine, menthol, lemon extract, mustard flavor, peppermint extract, spearmint extract, jasmine extract, or Glycyrrhiza extract.